Halozyme reports 42% Q1 revenue growth, announces $1B buyback program

Filed May 11, 2026 · Period ending May 11, 2026 · ~1 min read

Key Changes

• high

  Q1 2026 revenue reached $376.7M (up 42% YoY), driven by royalty revenue of $240.7M (up 43%), primarily from DARZALEX SC, VYVGART Hytrulo, and Phesgo uptake. Net income was $150.0M vs. $118.1M in Q1 2025.

  Exhibit 99.1 verify on EDGAR →
• high

  New $1B share repurchase program authorized through Dec 2028, with at least $400M planned for 2026, reflecting strong cash generation and management confidence in business durability.

  Exhibit 99.1 verify on EDGAR →
• high

  Three new collaboration agreements signed: GSK for ENHANZE in oncology/ADCs, Oruka for Hypercon (ORKA-001 plus one target, mid-single digit royalties), and Vertex for Hypercon (three targets, $15M upfront). Royalties expected to begin in 2030s.

  Exhibit 99.1 verify on EDGAR →